Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Enalapril. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 14/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.91 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | USP2 | O75604 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.68 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Enalapril SCHEMBL28322902 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| Enalapril SCHEMBL13575793 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| Enalapril SCHEMBL678442 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| Enalapril SCHEMBL8089096 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| Enalapril SCHEMBL13933092 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| Enalapril SCHEMBL18 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| Enalapril SCHEMBL6159149 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| Enalapril SCHEMBL97 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| Enalapril SCHEMBL8433334 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| Enalapril SCHEMBL28323975 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2ABCB11MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 488 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050272649-A1 | Conjoint administration of morphogens and ACE inhibitors in treatment of chronic renal failure | STRYKER CORPORATION | 2005-12-08 | — | — | US | claimed |
| EP-1578360-A2 | CONJOINT ADMINISTRATION OF MORPHOGENS AND ACE INHIBITORS IN TREATMENT OF CHRONIC RENAL FAILURE | Curis, Inc. (US) | 2005-09-28 | — | — | EP | claimed |
| EP-0967221-B1 | PROCESS FOR PREPARING PHARMACOLOGICALLY ACCEPTABLE SALTS OF N-(1(S)-ETHOXYCARBONYL-3-PHENYLPROPYL)-L-ALANYL AMINO ACIDS | KANEKA CORP (JP) | 2005-05-25 | — | — | EP | claimed |
| US-6713628-B2 | BY-PRODUCT INHIBITION OF THE DIKETOPIPERAZINE DERIVATIVE BY CARRYING OUT IN AQUEOUS LIQUID A SERIES OF OPERATIONS UNDER GIVEN CONDITIONS IN THE SAME SOLVENT; MAKING ENALAPRIL MALEATE FOR EXAMPLE | KANEKA CORPORATION (JP) | 2004-03-30 | — | — | US | claimed |
| WO-2004019876-A2 | CONJOINT ADMINISTRATION OF MORPHOGENS AND ACE INHIBITORS IN TREATMENT OF CHRONIC RENAL FAILURE | CURIS, INC. (US) | 2004-03-11 | — | — | WO | claimed |
| US-20030105327-A1 | Process for preparing pharmacologically acceptable salt of N-(1(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanyl-amino acid | KANEKA CORPORATION (JP) | 2003-06-05 | — | — | US | claimed |
| US-6518436-B2 | Condensing an amino acid and N-(1(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanine-N-carboxy-anhydride; suppressing the by-product diketopiperazine derivative; making enalapril maleate | KANEKA CORPORATION (JP) | 2003-02-11 | — | — | US | claimed |
| US-20020087007-A1 | Process for preparing pharmacologically acceptable salt of N-(1(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanyl-amino acid | KANEKA CORPORATION (JP) | 2002-07-04 | — | — | US | claimed |
| US-6335453-B1 | BY-PROUDCT INHIBITION | KANEKA CORPORATION (JP) | 2002-01-01 | — | — | US | claimed |
| US-6204393-B1 | IN AQUEOUS SOLUTION; CONTROLLING PH; NEUTRALIZATION | KANEKA CORPORATION (JP) | 2001-03-20 | — | — | US | claimed |
| EP-0180785-A1 | Pharmaceutical preparation containing a combination of Nitrendipin and Enalapril and process for its preparation | BAYER AG (DE) | 1986-05-14 | — | — | EP | claimed |
| EP-0166257-A2 | Cardiovascular composition | MERCK FROSST CANADA INC. (CA) | 1986-01-02 | — | — | EP | claimed |
| US-4558037-A | A DIBENZOTHIEPIN COMPOUND AND AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR | MERCK & CO., INC. (US) | 1985-12-10 | — | — | US | claimed |
| EP-0160307-A2 | Angiotensin converting enzyme inhibitors useful in the treatment of renal diseases | MERCK & CO. INC. (US) | 1985-11-06 | — | — | EP | claimed |
| EP-0129136-A2 | Antihypertensive composition | MERCK & CO. INC. (US) | 1984-12-27 | — | — | EP | claimed |
| US-4472384-A | INTERPHENYLENE 9-THIA-11-OXO-12-AZA PROSTANOIC ACID DERIVATIVE AND CARBOXYALKYLDIPEPTIDE | MERCK & CO., INC. (US) | 1984-09-18 | — | — | US | claimed |
| US-4472380-A | CARBOXYALKYL DIPEPTIDE DERIVATIVES | MERCK & CO., INC. (US) | 1984-09-18 | — | — | US | claimed |
| EP-0079521-A1 | Process for preparation of carboxyalkyldipeptide derivatives | MERCK & CO. INC. (US) | 1983-05-25 | — | — | EP | claimed |
| US-4374829-A | Aminoacid derivatives as antihypertensives | MERCK & CO., INC. (US) | 1983-02-22 | — | — | US | claimed |
| EP-0012401-A1 | Carboxyalkyl dipeptide derivatives, process for preparing them and pharmaceutical composition containing them | MERCK & CO. INC. (US) | 1980-06-25 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105327-A1 | Process for preparing pharmacologically acceptable salt of N-(1(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanyl-amino acid | SLC7A1, ASS1, ALDH7A1 | ACE 67/4885LMNA 765/4885SMN1; SMN2 496/4885 |
| US-20020087007-A1 | Process for preparing pharmacologically acceptable salt of N-(1(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanyl-amino acid | SLC7A1, ASS1, ALDH7A1 | ACE 67/4885LMNA 765/4885SMN1; SMN2 496/4885 |
| US-20050272649-A1 | Conjoint administration of morphogens and ACE inhibitors in treatment of chronic renal failure | BMPR2, BMP2, BMP1 | ACE 12/4885LMNA 3498/4885SMN1; SMN2 4471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.